Rezolut and CureMetrix Embark On AI Innovation Partnership
Rezolut, LLC and CureMetrix, Inc. have launched a pilot program in the Greater New York City area with the aim of pairing advanced technology with operational excellence to improve breast cancer detection in women receiving routine screening mammograms. Rezolut, LLC is a national, emerging platform of diagnostic medical imaging services, serving patients across the United States with 23 outpatient imaging centers and more than 50 mobile mammography units. Rezolut has a special focus on women’s imaging and is rapidly expanding its presence through organic growth and strategic partnerships in women’s healthcare.
“The CureMetrix partnership fits well with Rezolut’s vision to provide top-notch patient care partnered with innovative technology — to achieve better health outcomes,” said Eddie Suttiratana, Vice President of Northeast Operations.
CureMetrix delivers Artificial Intelligence (AI) solutions for screening mammography exams. The CureMetrix portfolio of clinical applications helps radiologists and healthcare professionals improve clinical and operational outcomes while reducing total cost of providing screening services. The end-to-end AI-based solutions from CureMetrix begin with cmTriage® — a worklist optimization tool that allows for the prioritization of suspicious exams. All exams are then processed by cmAssist® — an AI-based Computer Aided Detection (CAD) algorithm that seamlessly identifies, marks, and quantifies suspicious lesions.
The expected results of the pilot program are to show that the partnership can result in improved operational efficiencies across Rezolut’s mammography workflow while improving patient outcomes by increasing cancer detection rates and reducing false positives.
Rezolut and CureMetrix have a history of working together on innovation. The two companies conducted a two-year trial of the cmAssist CAD application in the Los Angeles market with Rezolut’s Shin Imaging centers.